Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۰۰ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
hct ci score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–0
  • Intermediate Risk1–2
  • High Risk3–27
Direct Clinical Answer

The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) calculates predicting survival after HCT in patients with hematologic malignancies, including optional age adjustment. Key inputs include arrhythmia. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.

Clinical Indication

The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is indicated for bedside clinical practice to support Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Sum of points assigned to each comorbidity: Arrhythmia (1), Cardiac CAD/CHF/MI/EF≤50% (1), Cardiac valve disease (3), IBD (1), Diabetes treated (1), Cerebrovascular (1), Psychiatric (1), Mild hepatic (1), Moderate/severe hepatic (3), Obesity BMI>35 (1), Infection (1), Rheumatologic (2), Peptic ulcer (2), Moderate/severe renal (2), Moderate pulmonary (2), Severe pulmonary (3), Prior solid tumor (3). Age adjustment adds 1 point if age ≥40 years.

Input Parameters

NameTypeRequiredDescription
arrhythmiastringYesHistory of arrhythmia
cardiacstringYesCardiac dysfunction
inflammatory_bowelstringYesInflammatory bowel disease
diabetesstringYesDiabetes
cerebrovascularstringYesCerebrovascular disease
psychiatricstringYesPsychiatric disturbance
hepaticstringYesHepatic dysfunction
obesitystringYesObesity (BMI > 35 kg/m²)
infectionstringYesInfection requiring antimicrobial treatment after day 0
rheumatologicstringYesRheumatologic disease
peptic_ulcerstringYesPeptic ulcer disease
renalstringYesRenal dysfunction
pulmonarystringYesPulmonary dysfunction
prior_solid_tumorstringYesPrior solid tumor (treated at any time, excluding non-melanoma skin cancer)
include_agestringYesInclude age adjustment (Sorror 2014)
ageintegerNoPatient age in years (required if age adjustment is included)(years)

Score Interpretation & Guidance

RangeStageDescription
0–0Low RiskScore 0
1–2Intermediate RiskScore 1-2
3–27High RiskScore ≥3

Evidence-Based References (EBM)

  • Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9.
  • Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10;32(29):3249-56.
  • Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014 Jul 10;124(2):287-95.

Related calculators